RG-6457

N/A

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameRG-6457
Drug Alias NameRO-7589831RG-6457VVD-133214VVD-214
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN inhibitors
TargetsBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
Therapy Area/IndicationsSolid tumoursColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesF. Hoffmann-La Roche Ag
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesVividion Therapeutics IncBayer Healthcare Company Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A